Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Happy to share that, 2023 was a great year of execution at Biodesix |
| In addition, our team continues to deliver on test process automation and workflow optimization projects that have driven a steady increase in gross margins over the course of 2023, ending the fourth quarter with 77% gross margin, an increase of 11 points over fourth quarter of 2022 |
| We bring tremendous value |
| We increased our gross margins over the course of the year to 77% and we improved our fourth quarter adjusted EBITDA by 55% over the comparable period |
| 2024 is a year of execution on our three goals, driving increased revenue by accelerating the adoption of our lung diagnostic tests and biopharma services, implementing operational efficiencies to improve gross margins, and maintaining a strict cost discipline |
| The improvement in adjusted EBITDA in both the fourth quarter and for the full year demonstrates our focus on actively managing our operating expenses, our success in improving gross margins and driving growth in top line revenue resulting in a decrease to our cash burn |
| With first-mover status in lung nodule management and an ever-increasing body of robust clinical data, we're building the momentum we've already created as we increase our clinical and payer adoption in this extremely large and underserved population |
| We've worked long and hard to build the best pulmonology-focused sales team in diagnostics and believe that this is just the beginning of our growth as we just scratched the surface with less than 1% penetration of this addressable market |
| We believe this new facility provides another competitive advantage as it enables us to grow and expand in an efficient and effective manner |
| The decrease in net loss for both the quarter and the full year was driven primarily by the increase in revenue, improvements in gross margins, and reduction in certain operating expenses including R&D expense as well as a reduction in non-cash stock-based compensation |
| Our industry-leading commercial team was responsible for driving this outstanding growth in 2023 |
| We also validated the benefit of adding associate sales consultants into existing territories, working alongside established team members to improve account retention and penetration, while building a bench for future expansion |
| However, it's important to note that the number of incoming requests have continued to be strong in the first eight weeks of 2024 and we have a robust pipeline |
| We built a commercial and operational platform that will help facilitate long-term, consistent, sustainable growth, and I believe everyone is to appreciate the leverage that exists within the business model and our efforts to demonstrate the team's significant progress and outstanding execution on our path to profitability |
| Adjusted EBITDA in the fourth quarter improved 55% over the same period in 2022 |
| This year, we delivered 65% lung diagnostic test volume growth, saw a return to growth in our biopharma services business, expanded our sector leading gross margins to the mid-70s, and improved adjusted EBITDA by 24% |
| So, we believe that we can continue to achieve those strong numbers |
| We've improved our already strong gross margins and made substantial progress on our path to profitability |
| By aligning these three strategic efforts, we're confident in our ability to sustain our aggressive growth trajectory, make progress on our path to profitability, and deliver value to the healthcare professionals, their patients, and all shareholders |
| We believe that this is an engine that will enable us to fuel future growth and potentially add additional products in addition to the MRD product |
| Moving on to our biopharmaceutical services business, we generated exceptional momentum in the second half of the year with more than 35% year-over-year growth in each of the last two quarters |
| We are encouraged with the strong growth this quarter and are pleased to see an increasing number of samples received from several different biopharma companies, running multiple clinical studies and an increasing number of incoming RFPs and opportunities |
| We've again achieved impressive and high double-digit growth in the past quarter attributed to the exceptional performance of our consultative lung-focused commercial team who've been instrumental in fueling our success |
| We've been exceptionally effective in providing our tests with industry-leading turnaround times and have made great strides in becoming even more efficient in the delivery of those tests |
| I guess related to the outlook here, you're making really nice progress on the margin front and sort of reducing operational burn |
| Maybe to start here on revenue guidance for the year, it's nice to see that solid growth outlook that you did talked about |
| The steady improvement across 2023 resulted in full year gross margins of 73% versus 63% for the full year 2022 |
| We anticipate the ability to maintain margins in the mid-70s going forward |
| Test volume in the quarter was our sixth straight quarter of at least 50% year-over-year growth |
| This is the sixth straight quarter of at least 50% year-over-year growth, primarily driven by our notified CDT and XL2 lung testing volumes |
| Statement |
|---|
| As we've discussed in prior earnings calls, we continue to experience delays in some Medicare Advantage payments for our Medicare covered tests from certain payers |
| It would be really challenging if we were static and not continuing to expand the sales force |
| As we continue to grow, the year-over-year comps become more and more challenging |
| The decrease in contracted revenue from the third quarter is something we typically see as we complete contracts and record higher revenue totals like we did in the second half of the year |
| And while we had a strong quarter, we did experience a delay in the receipt of samples for a large project resulting in approximately $600,000 in revenue pushing from the fourth quarter into the first half of 2024 |
| We see insurance companies slow down a little bit towards the end of the year |
| Actual events or results may differ materially from those projected as a result of changing market trends, reduced demand and the competitive nature of the diagnostics industry |
| We were limited in what we were able to do |
| Given our prioritization of kind of progressing towards profitability, Kyle, we've slowed commercialization of those |
| We've highlighted historically that chest or ACCP has been delayed |
| The one thing we're mindful of is as we continue to expand into territories where we haven't had representation prior, that ramp may be a little bit slower |
| Net loss for the full year ended 2023 was 52.1 million compared to a 65.4 million net loss for the full year 2022 |
| We were never really striving to see could we get them to $2 million |
| I mean, does that affect you at all? I'm just wondering if these things are maybe like drivers of performance like in this year that wouldn't be affected or included, I mean, in this guidance range |
Please consider a small donation if you think this website provides you with relevant information